Biomea Fusion, Inc. (BMEA) Latest Stock News & Headlines
WEBGet the latest Biomea Fusion, Inc. (BMEA) stock news and headlines to help you in your trading and investing decisions.
Biomea Fusion Highlights Recent Updates and Anticipated 2024 …
WEBJan 9, 2024 · Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases.
Biomea Fusion, Inc. (BMEA) Stock Price, News, Quote & History
WEBFind the latest Biomea Fusion, Inc. (BMEA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Biomea Fusion Announces FDA Clearance of Investigational New …
WEBOct 5, 2023 · BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes. The FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial of BMF-219 in adults with type 1 diabetes (T1D).
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
WEBDec 12, 2023 · Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.
FDA places full hold on Biomea Fusion’s diabetes trials of BMF-219
WEBJun 7, 2024 · The US Food and Drug Administration (FDA) has placed a full clinical hold on Biomea Fusion’s ongoing Phase I/II clinical trials assessing BMF-219 for type 1 and type 2 diabetes. The hold affects the COVALENT-111 and COVALENT-112 trials of BMF-219, a covalent menin inhibitor.
Biomea Fusion Announces FDA and Health Canada Clearance of
WEBSep 28, 2023 · Based on these and other scientific findings, Biomea is exploring the potential for BMF-219-mediated menin inhibition as a viable therapeutic approach to potentially halt or reverse progression...
Biomea Fusion Highlights Initial Data from the First Two Type 1 ...
WEBApr 1, 2024 · We are highlighting initial response data from a data cut-off of March 7, 2024 from our first two patients with Stage 3 type 1 diabetes who have received BMF-219 in the open-label portion of ...
Biomea Fusion Inc (BMEA) Stock Price & News - Google Finance
WEBGet the latest Biomea Fusion Inc (BMEA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Biomea Fusion Announces Positive Data from Initial Cohorts of …
WEBMar 28, 2023 · Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28